Triflusal is primarily used as an antiplatelet agent to prevent blood clots, making it valuable in the treatment and prevention of cardiovascular diseases such as stroke and myocardial infarction. It works by inhibiting the production of thromboxane, a substance that promotes platelet aggregation, while preserving the synthesis of prostacyclin, which helps maintain vascular health. This dual action reduces the risk of thrombotic events without significantly increasing the risk of bleeding, making it a favorable option for patients with a history of cerebrovascular or heart conditions. Additionally, triflusal has shown potential in neuroprotective applications, particularly in reducing inflammation and oxidative stress in the brain, which may benefit patients with neurodegenerative disorders. Its anti-inflammatory properties also extend to other conditions, such as rheumatoid arthritis, where it helps alleviate symptoms by modulating inflammatory pathways.